Heipram (Escitalopram)

Heipram is prescribed for the treatment of several psychiatric disorders that involve mood and anxiety dysregulation.

• Major depressive disorder (MDD) in adults.
• Generalized anxiety disorder (GAD) as a first‑line option.
• Social anxiety disorder (SAD) to reduce fear of social situations.
• Panic disorder, including agoraphobia, to lessen panic attacks.
• Adjunctive therapy for patients who have not responded adequately to other antidepressants.
• Off‑label use in certain obsessive‑compulsive or stress‑related conditions, when clinically appropriate.

The safety profile of Heipram reflects the typical effects observed with escitalopram therapy.

Common

• Nausea or upset stomach.
• Headache.
• Insomnia or somnolence.
• Dry mouth.
• Increased sweating.
• Dizziness.

Serious

• Suicidal thoughts or behavior, especially in younger adults.
• Serotonin syndrome (e.g., agitation, rapid heart rate, fever).
• Severe allergic reaction (e.g., rash, swelling, difficulty breathing).

Healthcare providers consider several precautionary factors before initiating Heipram therapy.

• Assess for a personal or family history of bipolar disorder or mania.
• Evaluate risk of suicidal ideation, particularly during the first weeks of treatment.
• Use cautiously in patients with hepatic or renal impairment; dose adjustments may be needed.
• Discuss potential effects on pregnancy and breastfeeding, as safety data are limited.
• Monitor for hyponatremia in elderly patients or those on diuretics.
• Avoid abrupt discontinuation to reduce the risk of withdrawal symptoms.

Escitalopram can interact with a range of other medicines; clinicians review concomitant drugs before prescribing Heipram.

Avoid

• Monoamine oxidase inhibitors (MAOIs) and other serotonergic agents (e.g., tramadol, linezolid) due to risk of serotonin syndrome.
• Pimozide, as combined use may cause serious cardiac effects.
• Certain anti‑platelet or anticoagulant drugs that increase bleeding risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which may heighten bleeding tendencies.
• Other antidepressants or antipsychotics that affect QT interval.
• CYP2C19 or CYP3A4 inhibitors/inducers (e.g., fluconazole, carbamazepine) that can alter escitalopram plasma levels.